Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Clin Cancer Res. 2022 Jun 1;28(11):2204-2205. doi: 10.1158/1078-0432.CCR-22-0116.

Abstract

The ADAURA adjuvant randomized trial demonstrated that osimertinib prolonged DFS. It has now been reported that health-related quality of life (HRQoL) was not adversely affected by adjuvant osimertinib. Does this mean that adjuvant osimertinib should now be standard as we await survival results? See related article by Majem et al., p. 2286.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Quality of Life

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors